Clinical trial · Observational
18F-FAPI PET/CT and MRI in Gastric Cancer
A Prospective Clinical Study on the Application of 18F-FAPI PET Imaging Combined With Multi-parameter MRI in the Diagnosis of Gastric Cancer
NCT07510867CI-TRIAL-00107358not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study was to evaluate the diagnostic efficacy and prognostic value of 18F-FAPI PET/CT combined with multiparameter MRI in gastric cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| patients with suspected or confirmed gastric cancer who have undergone 18F-FAPI PET/CT and MRI (non-contrast + contrast-enhanced scans) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Diagnostic efficacy
- timeFrame
- through study completion, an average of 1.5 year
- description
- Sensitivity, specificity, positive and negative predictive value of 18F-OC PET/CT and PET/MR Imaging in neuroendocrine neoplasms
Secondary outcomes (2)
- measure
- Standard uptake value （SUV）of tumor
- timeFrame
- through study completion, 3-4 years
- description
- This measure evaluates the association between baseline 18F-FAPI PET parameters (e.g., SUVmax, SUVmean).
- measure
- Prognostic Value of Baseline 18F-FAPI PET for Progression-Free Survival (PFS) in High-Risk Patients
- timeFrame
- through study completion, 3-4 years
- description
- PFS will be defined as the time from diagnosis to disease progression or relapse, assessed using the Kaplan-Meier method and Cox proportional hazards model.（PFS in months）
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients suspected or diagnosed with gastric cancer 2. 18F-FAPI PET/CT has been performed 3. Gastric MRI with both non-contrast and contrast-enhanced scans performed Exclusion Criteria: 1. Concurrent presence of other active malignant tumors or a history of other malignant tumors within the past 5 years; 2. Severe uncontrollable diseases or active infections; 3. Ineligible participants who cannot provide informed consent for the study; 4. Patients with suboptimal image quality in 18F-FAPI PET/CT 5. Patients with suboptimal MRI image quality enhancement
References
Publications (0)
Data not yet available
No reference posted for this study.